ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS announced the completion of the final report for the Good Laboratory Practice (GLP) safety study in non-human primates of the ES2B-C001 (HER2-VLP) breast cancer vaccine candidate. This significant milestone marks an important step towards enabling a clinical trial application. The Company is currently focusing on Good Manufacturing Practice (GMP) production and designing the Phase I clinical trial, with the aim to initiate the Phase I trial within the next year.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.414 SEK | -1.94% | -4.59% | -33.08% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.08% | 6.85M | |
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-12.32% | 33.03B | |
+54.69% | 24.68B | |
-17.39% | 15.12B | |
-9.14% | 12.81B | |
-10.48% | 11.79B | |
-42.45% | 11.64B | |
+7.27% | 8.9B |
- Stock Market
- Equities
- EXPRS2 Stock
- News ExpreS2ion Biotech Holding AB
- ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate